Shares of OpGen Inc (NASDAQ:OPGN) have received an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12-month consensus target price of $5.60 for the company and are expecting that the company will post ($0.53) earnings per share for the current quarter, according to Zacks. Zacks has also assigned OpGen an industry rank of 100 out of 255 based on the ratings given to its competitors.
A number of research firms have recently issued reports on OPGN. Zacks Investment Research upgraded shares of OpGen from a “sell” rating to a “hold” rating in a research note on Wednesday, June 27th. ValuEngine upgraded shares of OpGen from a “hold” rating to a “buy” rating in a research note on Tuesday, July 10th. Finally, HC Wainwright set a $8.00 price objective on shares of OpGen and gave the company a “buy” rating in a research note on Friday, August 3rd.
OpGen (NASDAQ:OPGN) last posted its quarterly earnings data on Thursday, August 2nd. The medical research company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.03. The company had revenue of $0.79 million for the quarter, compared to analyst estimates of $0.79 million. OpGen had a negative net margin of 373.39% and a negative return on equity of 241.59%. Equities analysts expect that OpGen will post -2.13 earnings per share for the current fiscal year.
An institutional investor recently bought a new position in OpGen stock. B. Riley Financial Inc. purchased a new position in OpGen Inc (NASDAQ:OPGN) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 138,000 shares of the medical research company’s stock, valued at approximately $246,000. B. Riley Financial Inc. owned about 2.22% of OpGen at the end of the most recent quarter. Hedge funds and other institutional investors own 11.36% of the company’s stock.
OpGen Company Profile
OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.
Further Reading: How to Invest in the Dividend Aristocrat Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.